Sun, Dec 21, 2014, 7:32 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Generex Biotechnology Corp. Message Board

  • tarponrgrt tarponrgrt Dec 14, 2010 7:30 PM Flag

    So How Many Months Does GNBT Have

    Cash left to pay for trials, overhead etc????
    Can any of you blind pumpers give an honest answer?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • First of all, I am not a pumper or basher. I believe that the answer is until April of 2011, I think I recall hearing that number from a press conference. I hope that they FINALLY do something with Metformin really soon, they've had that trial done for years. Obviously they will have to dilute the shareholders, as I do not believe that the trial is even fully enrolled yet as wouldn't there have been a press release if fully enrolled. Than add on six months (how long they test each subject) and there you get when the trial results should be given to Generex, or maybe a little bit longer to compile the data. 2011 should be an exciting year for Generex as well as Antigen Express. I believe that Generex is a buy, however I would be careful with this company and their finances.

      • 1 Reply to alex.maxwell21
      • Thank you for the honest answer. However, I think you might want to calculate again. I see Feb. or possibly Mar. until they run out of cash on hand.
        They can sell more shares (dilution) to raise cash.
        They can get a sweetheart financing deal (ex. Seaside 88). That worked out well, didn't it?

        They could partner or pray for a buyout?
        Partnership seems unlikely at this point.
        Buyout? Why? A buyout now with a 10% premium would be roughly $.36 a share.

        It looks like BK to me at this point. IMO
        Best of luck, you're gonna need it.

 
GNBT
0.0143-0.0004(-2.85%)Dec 19 3:47 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.